Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)
China flag China · Delayed Price · Currency is CNY
10.03
-0.30 (-2.90%)
Sep 11, 2026, 3:04 PM CST

SHE:000403 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
2,4752,6312,6542,3252,3961,966
Other Revenue
1.241.141.053.279.595.27
2,4762,6332,6552,3292,4051,972
Revenue Growth
-1.16%-0.83%14.00%-3.18%21.98%87.80%
Cost of Revenue
1,5831,5441,3521,1301,1511,064
Gross Profit
893.271,0891,3031,1991,254907.93
Selling, General & Admin
411.52438.17437.26465.81565.05419
Research & Development
53.5455.9255.1879.6975.3635.63
Other Operating Expenses
2822.2622.0721.6916.815.28
Operating Expenses
502.75525.12509.9565.15666.86477.73
Operating Income
390.53563.97793.13633.7587.01430.2
Interest Expense
-22.28-18.19-10.67-9.63-12.03-10.78
Interest & Investment Income
49.1263.5278.0175.0868.2262.3
Currency Exchange Gain (Loss)
0.010.010.13-0.122.4-0.21
Other Non Operating Income (Expenses)
15.55-0.30.030.64-2.23-3.44
EBT Excluding Unusual Items
432.92609.01860.61699.67643.37478.06
Impairment of Goodwill
-78.6-78.6----103.18
Gain (Loss) on Sale of Investments
10.344.36.38-18.974.9374.21
Gain (Loss) on Sale of Assets
-0.170.76-0.12-0.540.440.27
Asset Writedown
-17.78-17.86-3.46-1.29-3.59-0.49
Legal Settlements
------2.14
Other Unusual Items
-16.47-17.3-10.879.2515.2411.28
Pretax Income
330.25500.3852.78688.11660.39458.01
Income Tax Expense
61.6680.77107.7476.6472.766.47
Earnings From Continuing Operations
268.59419.54745.04611.47587.69391.54
Minority Interest in Earnings
-0.82-0.270.280.64-0.56-0.48
Net Income
267.77419.27745.32612.11587.13391.06
Net Income to Common
267.77419.27745.32612.11587.13391.06
Net Income Growth
-59.06%-43.75%21.76%4.25%50.14%110.29%
Shares Outstanding (Basic)
950953956947950917
Shares Outstanding (Diluted)
950953956947950919
Shares Change
0.36%-0.28%0.88%-0.33%3.38%44.25%
EPS (Basic)
0.280.440.780.650.620.43
EPS (Diluted)
0.280.440.780.650.620.43
EPS Growth
-59.21%-43.59%20.71%4.60%45.23%45.78%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-332.53-549.39-198.92301.74145.5882.06
Free Cash Flow Per Share
-0.35-0.58-0.210.320.150.09
Dividend Per Share
0.150-0.3850.1540.0620.043
Dividend Growth
-44.28%-150.06%149.27%43.16%-
Gross Margin
36.08%41.37%49.08%51.48%52.13%46.05%
Operating Margin
15.77%21.42%29.88%27.21%24.41%21.82%
Profit Margin
10.81%15.93%28.08%26.28%24.41%19.83%
Free Cash Flow Margin
-13.43%-20.87%-7.49%12.96%6.05%4.16%
EBITDA
533.08696.19918.23770.71704.63538.01
EBITDA Margin
21.53%26.45%34.59%33.10%29.30%27.29%
D&A For EBITDA
142.55132.22125.1137.02117.62107.82
EBIT
390.53563.97793.13633.7587.01430.2
EBIT Margin
15.77%21.42%29.88%27.21%24.41%21.82%
Effective Tax Rate
18.67%16.14%12.63%11.14%11.01%14.51%
Revenue as Reported
2,6332,6332,6552,3292,4051,972